T3 50mcg/tab 40 Tabletten by Sterling Knight Pharmaceuticals

Usage

1. Confirm your anabolic base compound has been running for at least 7–10 days (fast esters) or 14–21 days (long esters) and that plasma levels are stable before introducing Sterling Knight T3 Liothyronine.
2. Begin Liothyronine at 25 mcg daily by splitting one scored tablet in half; take the morning dose with a full glass of water on an empty stomach or at least 30 minutes before food to maximise absorption.
3. Monitor your resting heart rate each morning before rising — a reading consistently below 85 bpm at the 25 mcg entry level indicates tolerance and supports advancement to 50 mcg at the start of week three.
4. At the 50 mcg maintenance phase, increase dietary protein intake toward the upper end of the 2.4–3.1 g per kg lean body mass range; distribute across a minimum of four meals to provide the anabolic base with a continuous amino-acid substrate for muscle protein synthesis.
5. Maintain your full anabolic base dose without interruption throughout the entire T3 period; reducing or stopping AAS before T3 cessation removes the protective androgenic signal and exposes lean tissue to uncompensated thyroid-driven catabolism.
6. Begin stepping T3 back down to 25 mcg daily for the final one to two weeks of the cutting block, then discontinue fully; transition into your standard AAS post-cycle therapy protocol only after Liothyronine has been cleared.

Warnings

Frequently asked questions

Why does T3 Liothyronine cause muscle loss when used without an anabolic base during a caloric deficit?

Without androgenic support, elevated T3 accelerates whole-body protein turnover and tips nitrogen balance negative — skeletal muscle becomes a fuel substrate alongside fat. Androgen-receptor activation from an established AAS base directly counteracts this by upregulating IGF-1 expression and satellite-cell repair, keeping net muscle protein balance above the catabolic breakeven point throughout the deficit.

Which anabolic compounds are most effective at protecting muscle mass when running T3 Liothyronine in a cut?

Testosterone esters (Propionate, Enanthate), Nandrolone Phenylpropionate, and Boldenone are the most documented anabolic scaffolds for T3-assisted cutting cycles. Fast-ester options like Testosterone Propionate are preferred because they reach steady-state plasma levels within 7–10 days, closing the catabolic-exposure window before Liothyronine is introduced.

How much additional dietary protein is required to offset the anti-anabolic effects of T3 in a caloric deficit?

Nitrogen-balance research supports a range of 2.4–3.1 g of protein per kilogram of lean body mass when thyroid hormones are pharmacologically elevated and calories are below maintenance. Hitting the upper end of that range, distributed across at least four meals, gives the anabolic base compound sufficient substrate to sustain muscle protein synthesis rates under the accelerated metabolic conditions T3 creates.

Are Sterling Knight T3 tablets scored for splitting, and how should the 50 mcg dose be divided if needed?

Sterling Knight T3 tablets feature a scored design that allows clean splitting into two 25 mcg halves. This is practical for athletes who begin their T3 protocol at a lower entry dose before advancing, or who prefer to divide the daily total across morning and midday administrations to smooth the plasma concentration curve and reduce peak-driven side effects.

How is the 40-tablet pack format convenient for a structured AAS-protected cutting cycle?

Forty tablets at 50 mcg each provide a total of 2,000 mcg of Liothyronine — sufficient for an 8-week cycle at 25 mcg daily or a shorter, higher-dose protocol. The pack count aligns with the typical duration of an AAS-anchored cutting phase, meaning one pack maps cleanly onto one complete cutting block without requiring partial use of a second pack. (2) angle_used

Manufacturer

Sterling Knight Pharmaceuticals' raw-material sourcing discipline for its T3 Liothyronine product centres on a single high-risk control point: Liothyronine sodium API arrives at a per-tablet load of 50 mcg — a mass so small that supplier-to-supplier variation in bulk API purity translates directly and disproportionately into finished-tablet potency error. To contain this risk, Sterling Knight specifies pharmaceutical-grade Liothyronine sodium from audited API manufacturers whose certificate-of-analysis data is cross-validated against in-house HPLC re-assay on every incoming raw-material lot before it enters the tablet production stream. This dual-verification gate — supplier CoA plus independent HPLC confirmation — means that no batch of Sterling Knight T3 enters granulation and compression on the basis of supplier documentation alone. LAL endotoxin testing is applied at the finished-tablet stage, and GMP-certified facility controls govern air classification, equipment sterility, and environmental monitoring throughout the compression and packaging operations.